ADHERENCE TO LONG THERAPY BY GLATIRAMERE ACETATE AT MULTIPLE SCLEROSIS

Abstract

Among new immune-modeling and anti-inflammatory preparations, changing the course of remitting multiple sclerosis, there was studied polypeptide glatiramere acetate, having immune-modeling, anti-inflammatory and neuroprotective qualities. There were given results of our own investigations for adherence to medications, changing MS course, especially to glatiramere acetate.

Keywords

multiple sclerosis / adherence / glatiramere acetate

References

[1] 1. Бойко, А.Н. Опыт длительного использования Бетаферона и Копаксона в повседневной практике неврологов - результаты 5-летнего лечения больных рассеянным склерозом в Московском городском центре рассеянного склероза / А.Н. Бойко, М.В. Давыдовская, Т.Л. Демина и др. // Журн. неврол. и психиатр. им. С.С. Корсакова. Рассеянный склероз: прил. к журн. - 2007. -№4. - С. 84-94.

[2] 2. Вейн, А.М. Панические атаки // Международный медицинский журнал. - 1997. - № 3 (3). - С. 75-79.

[3] 3. Гусев, Е.И. Некоторые вопросы терапии препаратами бета-интерферона / Е.И. Гусев, Т.Л. Демина, А.Н. Бойко, Н.В. Хачанова // Журн. неврол. и психиатр. им. С.С. Корсакова. Рассеянный склероз: прил. к журн. - 2003. - № 2. - С. 98-102.

[4] 4. Сидоренко, Т.В. Влияние мотивации, комплаентности и приверженности к терапии на эффективность длительного лечения неврологических больных / Т.В. Сидоренко, Н.В. Хачанова, А.Н. Бойко // Журн. неврол. и психиатр. им. С.С. Корсакова. Рассеянный склероз: прил. к журн. - 2006. - № 3. - С. 96-100.

[5] 5. Aharoni, R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice / R. Aharoni, R. Eilam, H. Domev et al. // Proc. Natl. Acad. Sci USA. - 2005. - Vol. 102(52). - P. 1945-1950.

[6] 6. Arnon, R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate / R. Arnon, R. Aharoni // J. Neural. Transm. - 2009. - Vol. 116(11). - P. 1443-1449.

[7] 7. Blanco, Y. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study / Y. Blanco, E.A. Moral, M. Costa et al. // Neurosci Lett. - 2006. - Vol. 406(3). - P. 270-275.

[8] 8. Brod, M. Understanding compliance issues for daily self-injectable treatment in ambulatory care settings / M. Brod, M. Rousculp, A. Cameron // Patient Prefer Adherence. - 2008. - Vol. 2. - P. 129-136.

[9] 9. Clerico, M. Adherence to interferon-beta treatment and results of therapy switching / M. Clerico, P. Barbero, G. Contessa, C. Ferrero, L. Durelli // J. Neurol. Sci. - 2007. - Vol. 259. - P. 104-108.

[10] 10. Comi, G. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group / Comi G, Filippi M, Wolinsky JS. // Ann. Neurol. - 2001. - Vol. 49(3). - P. 290-297.

[11] 11. Costello, K. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term / K. Costello, P. Kennedy, J. Scanzillo // Medscape J. Med. - 2008. - Vol. 10(9). - P. 225-229.

[12] 12. Cox, D. Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis / D. Cox, J. Stone // J. Neurosci Nurs. - 2006. - Vol. 38. - P. 167-171.

[13] 13. Cramer, J.A. A systematic review of adherence with medications for diabetes // Diabetes Care. - 2004. - Vol. 27. - P. 1218-1224.

[14] 14. de Oliveira, Tde M. Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience / Tde M. de Oliveira, A.P. Fiore, Y.D. Fragoso // Patient Prefer Adherence. - 2008,Feb.2 - Vol. 2. - P. 41-46.

[15] 15. Devonshire, V. The Global Adherence Project - a multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis [abstract]. / V. Devonshire, Y. Lapierre, R. MacDonell et al. - Presented at: 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 27-30, 2006. - Madrid, Spain. 2006.

[16] 16. DiMatteo, M.R. Depression is a risk factor for noncom-pliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence / M.R. DiMatteo, H.S. Lepper, T.W. Croghan // Arch. Intern. Med. - 2000. - Vol. 160(14). - P. 2101-2107.

[17] 17. Filippi, M. CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study / M. Filippi, J.S. Wolinsky, G. Comi // Lancet Neurol. - 2006. - Vol. 5(3). - P. 213-220.

[18] 18. Fiore, A.P.P. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months / A.P.P. Fiore, Y.D. Fragoso // Arq. Neuropsiquiatr. - 2005. - Vol. 63. - P. 738-740.

[19] 19. Ford, C.C. the Copaxone Study Group. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients / C.C. Ford, R.P. Joh-nson, R.P. Lisak et al. // Mult. Scler. - 2006. - Vol. 12. - P. 309-320.

[20] 20. Fraser, C. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis / C. Fraser, O. Hadjimichael, T. Vollmer // J. Neurosci Nurs. - 2001. - Vol. 33. - P. 231-239.

[21] 21. Fraser, C. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis / C. Fraser, O. Hadjimichael, T. Vollmer // J. Neurosci Nurs. - 2003. -Vol. 35. - P. 163-170.

[22] 22. Fraser, C. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis / C. Fraser, L. Morgante, O. Hadjimichael, T. Vollmer // J. Neurosci Nurs. - 2004. - Vol. 36. - P. 120-129.

[23] 23. Haas, J. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone) / J. Haas, M. Firzlaff // Eur. J. Neurol. - 2005. - Vol. 12. - P. 425-431.

[24] 24. Hadjimichael, O. Adherence to injection therapy in MS: Patient survey / O. Hadjimichael, T.L. Vollmer // Neurology. - 1999. -Vol. 52(Suppl 2). - P. A549.

[25] 25. Jacobs, L.D. Intramuscular Interferon beta-la for disease progression in relapsing multiple sclerosis / L.D. Jacobs, D.L. Cookfair, R.A. Rudick et al. // Ann. Neurol. - 1996. - Vol. 39. - P. 285-294.

[26] 26. Johnson, K.P. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial / K.P. Johnson, B.R. Brooks, J.A. Cohen et al. // Neurology. - 1995. - Vol. 45. - P. 1268-1276.

[27] 27. Mikol, D.D. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial / D.D. Mikol, F. Barkhof, P. Chang et al. // Lancet Neurol. - 2008. - Vol. 7(10). - P. 903-914.

[28] 28. Murray, M.D. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial / M.D. Murray, J. Young, S. Hoke et al. // Ann. Intern. Med. - 2007. - Vol. 146. - P. 714-725.

[29] 29. Noseworthy, J.H. Multiple Sclerosis / J.H. Noseworthy, C. Lucchinetti, M. Rodriguez, B.G. Weinshenker // N. Engl. J.Med. - 2000. - Vol. 343. - P. 938-952.

[30] 30. O'Rourke, K.E. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns / K.E. O'Rourke, M. Hutchinson // Mult. Scler. - 2005. - Vol. 11. - P. 46-50.

[31] 31. Parker, D. Improving adherence and compliance: 90 days high risk compliance call questions / D. Parker, B. Beach. - Personal communication 2006, Global Seminar on Nurse and Patient Education; 30th-31st January; Lucerne, Switzerland. Annual Meeting; May 30th-June 2nd, 2007; Washington DC. Consortium of Multiple Sclerosis Centers - Poster, 2006. - S.56.

[32] 32. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial // Lancet. - 2009. - Vol. 374(9700). - P. 1503-1511.

[33] 33. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis // Lancet. - 1998. - Vol. 352(9139). - P. 1498-1504.

[34] 34. Rio, J. Factors related with treatment adherence to inter-feron b and glatiramer acetate therapy in multiple sclerosis / J. Rio, J. Porcel, N. Tellez et al. // Mult Scler. -2005. - Vol. 11. - P. 306-309.

[35] 35. Rovaris, M. European/Canadian Glatiramer Acetate Study Group. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European /Canadian double-blind, placebo-controlled, MRI monitored trial / M. Rovaris, G. Comi, M. Rocca, et al. // Mult Scler. - 2007. - Vol. 13. - P. 502-508.

[36] 36. Ruggieri, R.M. Long-term interferon-beta treatment for multiple sclerosis / R.M. Ruggieri, N. Settipani, L. Viviano et al. // Neurol Sci. - 2003. - Vol. 24. - P. 361-364.

[37] 37. The IFNB Multiple Sclerosis Study Group.Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial // Neurology. - 1993. - Vol. 43(4). - P. 655-661.

[38] 38. Tremlett, H.L. Stopping and switching of the Я-interferons prescribed for MS / H.L. Tremlett, J. Orger // Neurology. - 2003. - Vol. 61. - P. 551-554.

[39] 39. Turner, A.P. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model / A.P. Turner, D.R. Kivlahan, A.P. Sloan, J.K. Haselkorn // Mult. Scler. - 2007. -Vol. 13. - P. 1146-1152.

[40] 40. Weinshenker, B.G. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability / B.G. Weinshenker, B. Bass, G.P. Rice et al. // Brain. - 1989. - Vol. 112. - P. 133-146.

[41] 41. Wolinsky, J.S. Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. / J.S. Wolinsky, P.A. Narayana, K.P. Johnson // Mult. Scler. - 2001. - Vol. 7(1). - P. 33-41.

[42] 42. Wolinsky, J.S. Copolymer 1: a most reasonable alternative therapy for early relapsing remitting multiple sclerosis with mild disability // Neurology. - 1995. - Vol. 45. - P. 1245-1247.

[43] 43. World Health Organization. Adherence to long term therapies: evidence for action. Geneva: World Health Organization, 2003. Chapter I, section I.

[44] 44. Young, V. Differential mechanisms of action of interferon-в and glatiramer acetate in MS // Neurology. - 2002. - Vol. 59. - P. 802-808.

[45] 45. Ziemssen, T. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis / T. Ziemssen, J. Hoffman, R. Apfel, S. Kern // Health Qual Life Outcomes. - 2008. - Vol. 5;6. - P. 67-72.

RIGHTS & PERMISSIONS

Sidorenko Т.V., Boyko А.N.